Abivax SA American Depositary Shares (ABVX)vsRevolution Medicines Inc (RVMD)
ABVX
Abivax SA American Depositary Shares
$101.53
-3.24%
HEALTHCARE · Cap: $8.19B
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Abivax SA American Depositary Shares generates 563% more annual revenue ($4.92M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ABVX earns a higher WallStSmart Score of 32/100 (F).
ABVX
Avoid32
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 16.1x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVX
The strongest argument for ABVX centers on Revenue Growth. Revenue growth of 35.2% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ABVX
The primary concerns for ABVX are Price/Book, EPS Growth, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ABVX profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
ABVX is growing revenue faster at 35.2% — sustainability is the question.
ABVX generates stronger free cash flow (-51M), providing more financial flexibility.
Bottom Line
ABVX scores higher overall (32/100 vs 24/100) and 35.2% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abivax SA American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies aimed at treating chronic inflammatory diseases and viral infections, with its lead candidate ABX464 currently in clinical trials for ulcerative colitis among other indications. The company distinguishes itself by utilizing a unique approach that integrates antibody-mediated therapies with proprietary compounds, addressing critical unmet medical needs in the healthcare sector. With a robust pipeline and a team of skilled scientists committed to advancing therapeutic innovation, Abivax presents an attractive investment proposition for institutional investors seeking to leverage growth opportunities within the immunotherapy landscape.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?